Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for an induction of an adaptive stress response - available online now at Leukemia! Thanks to all co-authors and funding support from @ASH_hematology@ConquerCancerFd@NIH
https://t.co/xpkeXMTVdO
Aaron Schimmer and I are excited to organize an @ASH_hematology Scientific Workshop "Mitochondria and Metabolism in Blood Cancer and Normal Hematopoiesis - From Discovery to Patients" on Friday, 12/5/25, 3-6pm in Orlando. Link below - email us if you are interested in speaking!
Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for an induction of an adaptive stress response - available online now at Leukemia! Thanks to all co-authors and funding support from @ASH_hematology@ConquerCancerFd@NIH
https://t.co/xpkeXMTVdO
Excited to share our new preprint identifying the mevalonate pathway as essential for chemoresistance of TP53 mutant AML, a huge unmet need in the field. Big thanks to Martin Carroll and all co-authors! Thanks to #ASH#ASCO & #NIH for funding support.
https://t.co/g4yDVFa4tc
Congratulations to Dr Sarah Skuli for her work on TP53 AML as presented as oral session today at #ASH2023. Huge unmet medical need. https://t.co/GEnhUxEqW0
Having strong women mentors and role models in this field is everything. I’m so lucky to have people like @lindemilesphd@SarahSkuli @MariaAmaya_27 @CLJonesLab #ASH23
Today at #ASH23, hear @SarahSkuli present on TP53 mutant #AML (Abstract 408) at 10:45a PT and Dr. Stephen Schuster give updates on two clinical trials for follicular lymphoma (Abstracts 601, 603). #lymsm@ASH_hematology@PennCancer